ZOM Projected Dividend Yield

Zomedica Corp ( AMEX : ZOM )

Zomedica is a biopharmaceutical company targeting health and wellness solutions for the companion pet. Co.'s primary drug product candidate is ZM-007, an oral suspension formulation of metronidazole, targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms. Co.'s second drug product candidate is ZM-012, a tablet formulation of metronidazole and a complementary formulation to ZM-007, targeting the treatment of acute diarrhea in dogs. Co.'s third drug product candidate is ZM-006, a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats.

20 YEAR PERFORMANCE RESULTS